Telix Pharmaceuticals Limited

MELBOURNE, Australia and LIEGE, Belgium, Sept. 27, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has welcomed Her Royal Highness, Princess Astrid, Princess of Belgium to Telix Manufacturing Solutions (TMS), the Company’s recently inaugurated production facility, in Brussels South (Seneffe) in the Wallonia region of Belgium. Located in the heart of Belgium’s ‘Radiopharma … Read more

MELBOURNE, Australia, June 21, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals. SENSEI is an ultra-miniature robotic gamma probe … Read more

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT (10.30pm AEST) and via live webcast.[1] The briefing … Read more

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT (10.30pm AEST) and via live webcast.[1] The briefing … Read more

MELBOURNE, Australia, June 19, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications. The STARBURST study (ClinicalTrials.gov Identifier: … Read more

MELBOURNE, Australia, June 18, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the Company’s carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications. The STARBURST study (ClinicalTrials.gov Identifier: … Read more

MELBOURNE, Australia, June 5, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023. The presentation will take place on Wednesday June 7 … Read more